MARKET WIRE NEWS

NewAmsterdam Pharma Company N.V. (NASDAQ : NAMS ) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.


Quote


Last:$35.04
Change Percent: 1.39%
Open:$34.59
Close:$34.56
High:$35.7
Low:$34.22
Volume:146,283
Last Trade Date Time:04/13/2026 12:41:04 pm

Stock Data


Market Cap:$3,956,205,152
Float:62,439,780
Insiders Ownership:1.15%
Institutions:35
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.newamsterdampharma.com
Country:NL
City:Naarden

Recent News Releases


Subscribe to Our Newsletter


Message Board Posts


investorshub : makinezmoney
investorshub : BottomBounce
investorshub : tw0122
investorshub : Monksdream

**MWN-AI FAQ is based on asking OpenAI questions about NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS).

Link Market Wire News to Your X Account

Download The Market Wire News App